A phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma

被引：0
|
作者：
Shoji, H. [1 ]
Miyamoto, H. [2 ]
Hara, H. [3 ]
Takahari, D. [4 ]
Machida, N. [5 ]
Esaki, T. [6 ]
Nagashima, K. [7 ]
Aoki, K. [8 ]
Honda, K. [9 ]
Nagata, Y. [1 ]
Miyamoto, T. [1 ]
Boku, N. [1 ]
Kato, K. [1 ]
机构：
[1] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan
[2] FIVERINGS CO LTD, Osaka, Japan
[3] Saitama Canc Ctr Hosp, Dept Gastroenterol, Saitama, Japan
[4] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan
[5] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[6] Kyushu Natl Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan
[7] Chiba Univ, Grad Sch Med, Dept Global Clin Res, Chiba, Japan
[8] Natl Canc Ctr, Div Mol & Cellular Med, Reseach Inst, Tokyo, Japan
[9] Natl Canc Ctr, Div Chemotherapy & Clin Res, Reseach Inst, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
772TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study).
    Takahari, Daisuke
    Shoji, Hirokazu
    Hara, Hiroki
    Esaki, Taito
    Machida, Nozomu
    Nagashima, Kengo
    Aoki, Kazunori
    Honda, Kazufumi
    Miyamoto, Takahiro
    Boku, Narikazu
    Kato, Ken
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression
    Abraham, Jame
    [J]. JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (12): : 428 - 430
  • [3] Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study).
    Hara, Hiroki
    Shoji, Hirokazu
    Takahari, Daisuke
    Esaki, Taito
    Machida, Nozomu
    Nagashima, Kengo
    Aoki, Kazunori
    Honda, Kazufumi
    Miyamoto, Takahiro
    Boku, Narikazu
    Kato, Ken
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [4] A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma
    Satoshi Murahashi
    Daisuke Takahari
    Takeru Wakatsuki
    Naoki Fukuda
    Takashi Ichimura
    Mariko Ogura
    Masato Ozaka
    Eiji Shinozaki
    Izuma Nakayama
    Tomohiro Matsushima
    Hiroki Osumi
    Keisho Chin
    Kensei Yamaguchi
    [J]. International Journal of Clinical Oncology, 2018, 23 : 92 - 97
  • [5] A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma
    Murahashi, Satoshi
    Takahari, Daisuke
    Wakatsuki, Takeru
    Fukuda, Naoki
    Ichimura, Takashi
    Ogura, Mariko
    Ozaka, Masato
    Shinozaki, Eiji
    Nakayama, Izuma
    Matsushima, Tomohiro
    Osumi, Hiroki
    Chin, Keisho
    Yamaguchi, Kensei
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (01) : 92 - 97
  • [6] Preliminary result of p1/2 study of ramucirumab plus nivolumab in patients with pretreated advanced gastric carcinoma
    Esaki, Taito
    Shoji, Hirokazu
    Takahari, Daisuke
    Hara, Hiroki
    Machida, Nozomu
    Nagashima, Kengo
    Aoki, Kazunori
    Honda, Kazufumi
    Miyamoto, Takahiro
    Boku, Narikazu
    Kato, Ken
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [7] Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric cancer who previously treated with first-line nivolumab plus chemotherapy
    Jeon, Youngkyung
    Jeong, Sun Young
    Jang, Jaeyeon
    Jung, Ye Ji
    Choi, Daeho
    Hong, Joohyun
    Kim, Seung Tae
    Kang, Won Ki
    Lee, Jeeyun
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [8] A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer
    Bando, Hideaki
    Shimodaira, Hideki
    Fujitani, Kazumasa
    Takashima, Atsuo
    Yamaguchi, Kensei
    Nakayama, Norisuke
    Takahashi, Takehiro
    Oki, Eiji
    Azuma, Mizutomo
    Nishina, Tomohiro
    Hironaka, Shuichi
    Komatsu, Yoshito
    Shitara, Kohei
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 91 : 86 - 91
  • [9] NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
    Cecchini, Michael
    Cleary, James M.
    Shyr, Yu
    Chao, Joseph
    Uboha, Nataliya
    Cho, May
    Shields, Anthony
    Pant, Shubham
    Goff, Laura
    Spencer, Kristen
    Kim, Edward
    Stein, Stacey
    Kortmansky, Jeremy S.
    Canosa, Sandra
    Sklar, Jeffrey
    Swisher, Elizabeth M.
    Radke, Marc
    Ivy, Percy
    Boerner, Scott
    Durecki, Diane E.
    Hsu, Chih-Yuan
    Lorusso, Patricia
    Lacy, Jill
    [J]. BRITISH JOURNAL OF CANCER, 2024, 130 (03) : 476 - 482
  • [10] NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
    Michael Cecchini
    James M. Cleary
    Yu Shyr
    Joseph Chao
    Nataliya Uboha
    May Cho
    Anthony Shields
    Shubham Pant
    Laura Goff
    Kristen Spencer
    Edward Kim
    Stacey Stein
    Jeremy S. Kortmansky
    Sandra Canosa
    Jeffrey Sklar
    Elizabeth M. Swisher
    Marc Radke
    Percy Ivy
    Scott Boerner
    Diane E. Durecki
    Chih-Yuan Hsu
    Patricia LoRusso
    Jill Lacy
    [J]. British Journal of Cancer, 2024, 130 : 476 - 482
12345